Price and safety profile (low risk and good tolerability) will be key factors for CF101, imo. If there is a safe and tolerable, cheap, oral drug, some docs might try it before moving to the more effective, expensive and not as benign (both risk and AEs aspects that is) options . If (and it's a big if), CF101's efficacy gets better with longer dosing, docs might use it in patients who become refractory to anti-TNFs ahead of a JAK inhibitor. All in all, even if used pre and post anti-TNFs, I don't expect it to have a substantial market uptake in RA (I see a better future for it in psoriasis).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.